Search research articles
Contact Us
Filters
Showing results (61-70 of 91) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
Michael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Molecular Cancer Therapeutics
|
September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Julia Judd, Nagla Abdel Karim, Hina Khan, et al.
The New England Journal of Medicine
|
June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> Mutation
Pasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Cancer Discovery
|
February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J Riely, Joel W Neal, D Ross Camidge, et al.
Clinical Lung Cancer
|
August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Myung J Ahn, Hye R Kim, James C H Yang, et al.
The Lancet. Oncology
|
June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Cell
|
May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang, Ling Feng Ye, Zheng Fu, et al.
ESMO Open
|
August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
D V T Catenacci, Y-K Kang, H H Yoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2021
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 91) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
Michael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 19, 2021
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Molecular Cancer Therapeutics
|
September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer
Julia Judd, Nagla Abdel Karim, Hina Khan, et al.
The New England Journal of Medicine
|
June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> Mutation
Pasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Cancer Discovery
|
February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J Riely, Joel W Neal, D Ross Camidge, et al.
Clinical Lung Cancer
|
August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Myung J Ahn, Hye R Kim, James C H Yang, et al.
The Lancet. Oncology
|
June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Cell
|
May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang, Ling Feng Ye, Zheng Fu, et al.
ESMO Open
|
August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
D V T Catenacci, Y-K Kang, H H Yoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2021
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, et al.
Page
of 10